TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s 2026 Antimicrobial Resistance Threats Report lists 19 pathogens across urgent, serious and concerning threat levels, plus six on a watch list. Together, the pathogens are estimated to cause 9.7 million infections and 50,800 deaths in the United States each year. Four drug-resistant pathogens are classified as urgent threats; the report also notes that C. difficile moved down to serious.
The CDC’s updated 2026 antimicrobial-resistance report identifies 19 pathogens as threats to public health and estimates that they cause 9.7 million infections and 50,800 deaths in the United States each year. Four drug-resistant pathogens — Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant gonorrhea — are in the agency’s highest, “urgent” category.
The report ranks pathogens as urgent, serious or concerning and also identifies six emerging pathogens for a watch list. The CDC says the watch-list organisms may pose potential threats, but their disease burden is uncertain. Among the additions are drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria.
Several pathogens have specific estimates in the report. U.S. cases of Candida auris, a multidrug-resistant yeast that can cause severe infections, rose from 48 reported cases in 2016 to 4,523 in 2023. Carbapenem-resistant Acinetobacter was linked to an estimated 9,497 U.S. hospitalizations and 817 deaths in 2023; carbapenem-resistant Enterobacterales to 14,878 hospitalizations and 1,252 deaths that year.
Drug-resistant Neisseria gonorrhoeae caused an estimated 787,000 U.S. infections in 2023. The report says 55.4% of gonorrhea cases that year were resistant to at least one of six antibiotics or showed elevated minimum inhibitory concentrations. Drug-resistant N. meningitidis was classified as a serious threat requiring prompt, sustained action.
The Burden on Patients and Care
The report’s estimates describe a substantial annual burden, but the risks are not evenly distributed. Some listed infections are particularly concerning for people who are already seriously ill or receiving care involving devices such as ventilators and catheters. Resistant infections can also limit treatment choices, making prevention and timely treatment important parts of healthcare.
Wendy Armstrong, president of the Infectious Diseases Society of America, said drug-resistant infections can prolong hospital stays and increase healthcare costs. She added that resistance can make it difficult, and sometimes impossible, for doctors to safely provide care such as cancer chemotherapy, organ transplants and joint replacements. Her remarks are an assessment of the clinical consequences, while the infection and death totals are the CDC’s estimates.
For readers, the report is a signal about risks across healthcare and community settings, not a prediction that an individual will contract one of these infections. Several urgent threats are associated with healthcare exposure or specific conditions, while gonorrhea is a sexually transmitted infection. The report’s categories describe public-health priorities, not an individual patient’s diagnosis or outcome.
Products Worth Considering
Levoit Vital 100S-P Air Purifier for Home and Pets
Withings BPM Connect Smart Blood Pressure Monitor
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
As an affiliate, we earn on qualifying purchases.
Why the Threat List Changed
The CDC’s 2026 report updates its assessment of the pathogens that can resist antimicrobial drugs. It places 19 pathogens in ranked threat categories and six more on a watch list, reflecting both established concerns and organisms whose potential impact remains uncertain.
One notable change is Clostridioides difficile, which moved from urgent to serious. The source report attributes the reclassification in part to successful infection-prevention measures and a decline in cases since 2011. That change does not mean C. difficile is no longer a public-health concern; it remains in a serious category.
The report also points to treatment developments and policy proposals. The FDA approved gepotidacin, marketed as Blujepa, and zoliflodacin, marketed as Nuzolvence, for gonorrhea in 2025; the source describes them as the first new antibiotics for gonorrhea in decades. Armstrong called for passage of the PASTEUR Act, a proposed federal program to support development of antimicrobial drugs for threatening infections. The bill’s House and Senate versions remain stalled in congressional committees, according to the source report.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Estimates and Watch List
The 50,800 annual deaths and 9.7 million infections are combined estimates for the pathogens in the report; they are not a count of deaths occurring in a single year or an estimate for any one organism. The source material does not provide a confidence range, the precise estimation method, or a breakdown of the combined totals by pathogen. Readers should not interpret the annual estimate as a direct measure of current-year cases.
The watch-list pathogens have an uncertain disease burden, and the report identifies them as potential threats rather than established top-tier threats. The source material also does not give detailed estimates for every pathogen or explain how each category may change over time. It remains unclear from the available details what future surveillance will show about the newer entries.
Surveillance and Policy Decisions Ahead
The CDC’s report sets out current threat categories and estimates; ongoing monitoring will be needed to track changes in infections, resistance patterns and the burden of organisms on the watch list. The supplied report details do not specify a date for the next update or a particular follow-up milestone.
On policy, the PASTEUR Act remains stalled in congressional committees, and the source material does not identify a vote date or legislative timetable. Drug approvals for gonorrhea add treatment options, but the CDC’s 2023 resistance findings show that resistance remains a concern. Further developments will depend on surveillance data, clinical treatment experience and decisions by lawmakers and public-health agencies.
Key Questions
What does the CDC estimate about these pathogens?
The 2026 report estimates that the 19 listed pathogens cause 9.7 million infections and 50,800 deaths annually in the United States. Those figures are combined estimates, not totals for one specific year.
Which pathogens are in the urgent category?
The four drug-resistant urgent threats named in the report are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower category?
The report moved Clostridioides difficile from urgent to serious, attributing the change in part to infection-prevention measures and declining case numbers since 2011. It remains classified as a serious threat.
What is the CDC watch list?
The watch list includes six potential emerging threats whose disease burden is uncertain. Entries include drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria.
Is the PASTEUR Act law?
No. According to the source report, the House and Senate versions of the proposed PASTEUR Act remain stalled in congressional committees. The available information does not give a timetable for further action.
Source: medpagetoday.com
